The US Food and Drug Administration (FDA) has approved Teligent Inc's (NASDAQ:TLGT) abbreviated new drug application (ANDA) for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%, a topical anaesthetic, the pharmaceutical company announced on Monday.
This is Teligent's seventh approval so far this year, and the 26th approval from its internally developed pipeline of topical generic pharmaceutical medicines.
IQVIA data from April 2018 suggests that the total addressable market for this product is approximately USD44m.
The company plans to launch the product in the US market in the third quarter of 2018.
Teligent now has 31 topical generic pharmaceutical products in its US portfolio, in addition to its four US injectable products.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US